These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 9308748

  • 21. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.
    Chalmers EA, Brown SA, Keeling D, Liesner R, Richards M, Stirling D, Thomas A, Vidler V, Williams MD, Young D, Paediatric Working Party of UKHCDO.
    Haemophilia; 2007 Mar; 13(2):149-55. PubMed ID: 17286767
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.
    Kempton CL, Abshire TC, Deveras RA, Hoots WK, Gill JC, Kessler CM, Key NS, Konkle BA, Kuriakose P, Macfarlane DE, Bergman G.
    Haemophilia; 2012 Sep; 18(5):798-804. PubMed ID: 22512291
    [Abstract] [Full Text] [Related]

  • 23. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
    Bacon CL, Singleton E, Brady B, White B, Nolan B, Gilmore RM, Ryan C, Keohane C, Jenkins PV, O'Donnell JS.
    Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
    [Abstract] [Full Text] [Related]

  • 24. Previously untreated patients and recombinant factor VIII concentrate studies.
    Pasi KJ.
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S29-32. PubMed ID: 9351534
    [Abstract] [Full Text] [Related]

  • 25. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
    Hellstern P, Kiehl R, Miyashita C, Schwerdt H, von Blohn G, Köhler M, Büttner M, Wenzel E.
    Thromb Haemost; 1986 Dec 15; 56(3):353-9. PubMed ID: 3105109
    [Abstract] [Full Text] [Related]

  • 26. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G, Spranger T, Brackmann HH.
    Haematologica; 2003 Jun 15; 88(6):EREP05. PubMed ID: 12826531
    [Abstract] [Full Text] [Related]

  • 27. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
    Wolf DM, Rokicka-Milewska R, Lopaciuk S, Skotnicki AB, Klukowska A, Laguna P, Windyga J, Kotitschke R, Struff WG.
    Haemophilia; 2004 Sep 15; 10(5):438-48. PubMed ID: 15357768
    [Abstract] [Full Text] [Related]

  • 28. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.
    Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B.
    Haematologica; 2005 Sep 15; 90(9):1288-90. PubMed ID: 16154861
    [Abstract] [Full Text] [Related]

  • 29. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group.
    Goodeve AC, Williams I, Bray GL, Peake IR.
    Thromb Haemost; 2000 Jun 15; 83(6):844-8. PubMed ID: 10896236
    [Abstract] [Full Text] [Related]

  • 30. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
    Mazurier C, Parquet-Gernez A, Goudemand M.
    Thromb Haemost; 1990 Oct 22; 64(2):251-5. PubMed ID: 2125374
    [Abstract] [Full Text] [Related]

  • 31. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L, Pitlik E.
    Haematologica; 2000 Oct 22; 85(10 Suppl):64-8. PubMed ID: 11187874
    [Abstract] [Full Text] [Related]

  • 32. Novel therapies for immune tolerance in haemophilia A.
    Collins PW.
    Haemophilia; 2006 Dec 22; 12 Suppl 6():94-100; discussion 100-1. PubMed ID: 17123401
    [Abstract] [Full Text] [Related]

  • 33. [Effect of factor VIII concentrates of very high purity on CD4+ cell count in hemophiliacs infected with HIV].
    Molina Alejandro R, Lorenzo Herrero JI, Haya Guaita S, Querol Fuentes F, Aznar Lucea JA.
    Rev Clin Esp; 1996 Jun 22; 196(6):365-9. PubMed ID: 8767071
    [Abstract] [Full Text] [Related]

  • 34. Investigation of an outbreak of hepatitis A in Irish haemophilia A patients.
    Lawlor E, Johnson Z, Thornton L, Temperley I.
    Vox Sang; 1994 Jun 22; 67 Suppl 1():18-9; discussion 20. PubMed ID: 8091729
    [Abstract] [Full Text] [Related]

  • 35. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate).
    Stadler M, Gruber G, Kannicht C, Biesert L, Radomski KU, Suhartono H, Pock K, Neisser-Svae A, Weinberger J, Römisch J, Svae TE.
    Biologicals; 2006 Dec 22; 34(4):281-8. PubMed ID: 16500114
    [Abstract] [Full Text] [Related]

  • 36. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
    Kaveri SV, Dasgupta S, Andre S, Navarrete AM, Repessé Y, Wootla B, Lacroix-Desmazes S.
    Haemophilia; 2007 Dec 22; 13 Suppl 5():61-4. PubMed ID: 18078399
    [Abstract] [Full Text] [Related]

  • 37. Inhibitors in patients with haemophilia A.
    Kreuz W, Ettingshausen CE.
    Thromb Res; 2014 Nov 22; 134 Suppl 1():S22-6. PubMed ID: 24745722
    [Abstract] [Full Text] [Related]

  • 38. Successful liver transplantation in a patient with severe haemophilia A and a high-titre factor VIII inhibitor.
    Ashrani AA, Reding MT, Shet A, Osip J, Humar A, Lake JR, Key NS.
    Haemophilia; 2004 Nov 22; 10(6):735-7. PubMed ID: 15569170
    [Abstract] [Full Text] [Related]

  • 39. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A.
    Goldenberg NA, Hathaway WE, Jacobson L, McFarland K, Manco-Johnson MJ.
    Haemophilia; 2006 Nov 22; 12(6):605-14. PubMed ID: 17083510
    [Abstract] [Full Text] [Related]

  • 40. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P, Plamenová I, Hollý P, Stasko J.
    Med Sci Monit; 2009 Jun 22; 15(6):CS105-11. PubMed ID: 19488019
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.